ArticleFrontiers in immunology2025
Study of the influence of population immunity to tick-borne encephalitis virus on the characteristics of the epidemic process in Russia.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mimicry by the Tick-Borne Encephalitis Virus E Protein: A Hidden Link to Autoimmunity.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tick-borne encephalitis (TBE) is a significant public health challenge in Russia. Vaccination is one of the most effective measures to control TBE. The aim of our study was to assess the state of anti-TBE virus population immunity, including artificial post-vaccine and natural post-infection immunity, in the context of characteristics of the epidemic process in Russia. Materials and methods: During the period from 2018 to 2020, we studied 28,395 conditionally healthy volunteers from various regions of Russia, without age and gender restrictions. Blood serum samples were tested for anti-TBE virus IgG antibodies. All volunteers completed questionnaires to collect demographic data, information about residence, TBE vaccination, and tick bites. Results: Our study included participants from non-endemic (Moscow and the Republic of Dagestan) and endemic regions (Moscow Region, St. Petersburg, Leningrad Region, Novosibirsk Region, Khabarovsk Region). In regions with the highest protection against TBE, such as Novosibirsk Region and Khabarovsk Region, the proportions of individuals with seropositive and protective antibody titers were below 45% and 35%, respectively. The lowest rate of protective immunity was found among children (25.4% in Novosibirsk Region and 22% in Khabarovsk Region) and those aged 60 and older (27.3% and 25.1%, respectively). Situation was even more challenging in St. Petersburg and Leningrad Region, where the rate of protective antibody titers ranged from 4.3% to 8.7%. The highest vaccination coverage was found among volunteers from Novosibirsk Region and Khabarovsk Region: 32.5% and 27.4%. In St. Petersburg and Leningrad Region, vaccination coverage was ranged from 10.4% to 11.3%, while in other regions it was below 6%. The rates of post-vaccine protective immunity were 63.1% in Khabarovsk Region, 71.6% in Novosibirsk Region and up to 50% in other regions. The rates of post-infection immunity were 33.4% in Novosibirsk Region, 42.4% in Khabarovsk Region and below 12% in other regions. Conclusions: Our results demonstrated diversity of population immunity level and structure in different regions of Russia. The analysis showed that study participants are at risk of TBE infection, especially high in endemic regions, due to insufficient level of population immunity, vaccination coverage, and protective post-vaccine immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.